Trial results

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

NCT03811561 on ClinicalTrials.gov · last registry update 2026-08-04

An unusually large phase 3: 1,500 participants, more than double the 424 typical for the stage. Due to report 7 November 2027, alongside 38 other tracked readouts that quarter. Primary outcome, as filed: Presence of at least 3 steps Early Treatment Diabetic Retinopathy Study (ETDRS) subject level progression. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 8 May 2019 — 7 years so far. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

ACTIVE_NOT_RECRUITING

Phase

P3

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Novo Nordisk A/S

Sponsor type

Industry

Enrollment

1,500

Started

2019-05-08

Primary completion

2027-11-07 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Presence of at least 3 steps Early Treatment Diabetic Retinopathy Study (ETDRS) subject level progression.

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.